Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.9 SEK | +2.67% | +7.10% | +9.31% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Sales 2024 * | 617M 56.29M | Sales 2025 * | 788M 71.88M | Capitalization | 567M 51.74M |
---|---|---|---|---|---|
Net income 2024 * | -107M -9.76M | Net income 2025 * | -28M -2.56M | EV / Sales 2024 * | 1.39 x |
Net Debt 2024 * | 289M 26.37M | Net Debt 2025 * | 201M 18.34M | EV / Sales 2025 * | 0.98 x |
P/E ratio 2024 * |
-5.29
x | P/E ratio 2025 * |
-19.8
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 day | +1.34% | ||
1 week | +1.93% | ||
Current month | +8.47% | ||
1 month | +2.05% | ||
3 months | +14.50% | ||
6 months | +3.05% | ||
Current year | +9.31% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 16.9 | +2.67% | 14 135 |
24-04-29 | 16.46 | -0.48% | 3,679 |
24-04-26 | 16.54 | -2.71% | 19,414 |
24-04-25 | 17 | 0.00% | 8,963 |
24-04-24 | 17 | +2.53% | 7,316 |
Delayed Quote Nasdaq Stockholm, April 30, 2024 at 06:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.31% | 51.89M | |
+3.37% | 69.85B | |
+11.77% | 8.98B | |
-14.44% | 4.89B | |
+41.60% | 4.44B | |
+5.96% | 3.95B | |
+23.38% | 2.49B | |
-19.32% | 2.4B | |
-27.04% | 2.28B | |
+7.97% | 1.96B |
- Stock Market
- Equities
- ORX Stock